Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

医学 结直肠癌 荟萃分析 肿瘤科 内科学 系统回顾 癌症 梅德林 政治学 法学
作者
Tanios Bekaii‐Saab,Krzysztof Lach,Ling‐I Hsu,Muriel Siadak,Mike Stecher,James E. Ward,Rachel Beckerman,John H. Strickler
出处
期刊:Oncologist [AlphaMed Press]
卷期号:28 (10): 885-893 被引量:21
标识
DOI:10.1093/oncolo/oyad200
摘要

Abstract Background HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. Methods A systematic review of MEDLINE, Embase, and Cochrane Library (2001-2021) identified studies evaluating progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in HER2-positive vs. HER2-negative patients with RAS WT mCRC who received anti-EGFR treatments and whose HER2 status was known. Meta-analyses of proportions (ORR) and hazard ratios (PFS, OS) were performed using random-effect models with pre-specified sensitivity analyses. Results Five high-quality retrospective cohort studies were included in the meta-analyses representing 594 patients with mCRC. All patients received anti-EGFR treatment, either as monotherapy or in combination with chemotherapy. Meta-analysis of PFS demonstrated a 2.84-fold higher risk of death or progression (95% CI, 1.44-5.60) in patients with HER2-positive (vs. HER2-negative) RAS WT mCRC treated with anti-EGFR regimens. The odds of response to anti-EGFR treatment were 2-fold higher in HER2-negative vs. HER2-positive (odds ratio, 1.96 [95% CI, 1.10-3.48]). Differences in OS were not statistically significant. Sensitivity analyses confirmed the robustness of the base-case estimates. Conclusions While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
科研通AI6.3的应助被hjy采纳,获得10
1秒前
高挑的保温杯完成签到,获得积分10
1秒前
丘比特的应助被特仑苏采纳,获得10
1秒前
张伟发布了新的文献求助10
2秒前
aqqq发布了新的文献求助10
2秒前
2秒前
Hus11221完成签到,获得积分10
2秒前
cwb发布了新的文献求助10
3秒前
小垃圾10号完成签到,获得积分10
3秒前
结实的忆枫完成签到,获得积分10
4秒前
悸动完成签到 ,获得积分10
4秒前
纪秋发布了新的文献求助10
4秒前
4秒前
4秒前
Rtian完成签到,获得积分10
5秒前
SUNstp发布了新的文献求助10
5秒前
酷酷李可爱婕完成签到 ,获得积分0
5秒前
h_jun完成签到 ,获得积分10
5秒前
kaida完成签到,获得积分10
5秒前
923完成签到,获得积分10
5秒前
yuan发布了新的文献求助10
5秒前
5秒前
djdj放技能完成签到 ,获得积分10
5秒前
5秒前
任11完成签到 ,获得积分10
6秒前
奋斗信封完成签到,获得积分10
6秒前
chijiadong完成签到,获得积分20
7秒前
7秒前
小胖完成签到,获得积分10
7秒前
Akim的应助被阿飞采纳,获得10
7秒前
8秒前
大石完成签到,获得积分10
8秒前
啪叽米完成签到 ,获得积分10
8秒前
武陵济世发布了新的文献求助10
9秒前
雨过天晴发布了新的文献求助10
9秒前
科研通AI6.4的应助被Borky采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253